Prostacyclin Regulates Bone Growth via the Epac/Rap1 Pathway

Endocrinology (United States)

Volumn 156, Issue 2, 2015, Pages 499-510

  Hutchison, Michele R ^a   White, Perrin C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMOADENOSINE; ADENOSINE DERIVATIVE; ANTIPORTER; BROXURIDINE; CELECOXIB; CYCLIC AMP; CYCLOOXYGENASE 2; ERK PROTEIN; EXCHANGE PROTEIN DIRECTLY ACTIVATED BY CAMP; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ILOPROST; MESSENGER RNA; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN E2; PROTEIN; RAP1 PROTEIN; SOMATOMEDIN C; UNCLASSIFIED DRUG; EPAC PROTEIN, MOUSE; GUANINE NUCLEOTIDE EXCHANGE FACTOR; PROSTACYCLIN DERIVATIVE; PTGS2 PROTEIN, MOUSE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTICULAR CARTILAGE; BONE GROWTH; BOVINAE; CARTILAGE CELL; CELL PROLIFERATION; CONTROLLED STUDY; DWARFISM; ENZYME ACTIVITY; EX VIVO STUDY; EXPLANT; GROWTH PLATE; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; BONE DEVELOPMENT; BOVINE; C57BL MOUSE; CELL CULTURE; DRUG EFFECTS; ENZYMOLOGY; FEMALE; MALE; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE DEVELOPMENT; CATTLE; CELECOXIB; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2; EPOPROSTENOL; FEMALE; GROWTH PLATE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; ILOPROST; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, INBRED C57BL; PROSTAGLANDINS I; PYRAZOLES; RAP1 GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84921669804     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1348     Document Type: Article

References (76)

1. Flanagan AM, Chambers TJ. Stimulation of bone nodule formation in vitro by prostaglandins E1 and E2. Endocrinology. 1992;130: 443-448
2. Olney RC, Mougey EB. Expression of the components of the insulinlike growth factor axis across the growth-plate. Mol Cell Endocrinol. 1999;156:63-71
3. Sims NA, Clment-Lacroix P, Da Ponte F, et al. Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but inDepenDent of Stat5. J Clin Invest. 2000;106:1095-1103
4. Olney RC, Wang J, Sylvester JE, Mougey EB. Growth factor regulation of human growth plate chondrocyte proliferation in vitro. Biochem Biophys Res Commun. 2004;317:1171-1182
5. Hutchison MR, Bassett MH, White PC. Insulin-like growth factor-I and fibroblast growth factor, but not growth hormone, affect growth plate chondrocyte proliferation. Endocrinology. 2007;148: 3122-3130
6. Hutchison MR. BDNF alters ERK/p38MAPKactivity ratios to promote differentiation in growth plate chondrocytes. Mol Endocrinol. 2012;26:1406-1416
7. Dueckers G, Guellac N, Arbogast M, et al. EviDence and consensus based GKJR guiDelines for the treatment of juvenile idiopathic arthritis. Clin Immunol. 2012;142:176-193
8. DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2012;64:1001-1010
9. DuBois RN, Awad J, Morrow J, Roberts LJ, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-And phorbol ester. J Clin Invest. 1994;93:493-498
10. Fletcher BS, Kujubu DA, Perrin DM, Herschman HR. Structure of the mitogen-inducible TIS10 gene and Demonstration that the TIS10-encoDed protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338-4344
11. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA. 1992;89:7384-7388
12. Weinreb M, Suponitzky I, Keila S. Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone. 1997;20:521-526
13. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Role of endogenous PGE2 in osteoblastic functions of a clonal osteoblastlike cell, MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids. 1994;50:169-172
14. Wang X, Li F, Fan C, Wang C, Ruan H. Analysis of isoform specific ERKsignaling on the effects of interleukin-1 on COX-2 expression and PGE2 production in human chondrocytes. Biochem Biophys Res Commun. 2010;402:23-29
15. Heinecke LF, Grzanna MW,Au AY,Mochal CA,Rashmir-Raven A, Frondoza CG. Inhibition of cyclooxygenase-2 expression and prostaglandin E2 production in chondrocytes by avocado soybean unsaponifiables and epigallocatechin gallate. Osteoarthritis Cartilage. 2010;18:220-227
16. Di Battista JA, Dor S, Martel-Pelletier J, Pelletier JP. Prostaglandin E2 stimulates incorporation of proline into collagenase digestible proteins in human articular chondrocytes: iDentification of an effector autocrine loop involving insulin-like growth factor I. Mol Cell Endocrinol. 1996;123:27-35
17. Schwartz Z, Swain LD, Kelly DW,Brooks B, Boyan BD. Regulation of prostaglandin E2 production by vitaminDmetabolites in growth zone and resting zone chondrocyte cultures is DepenDent on cell maturation. Bone. 1992;13:395-401
18. Lowe GN, Fu YH, McDougall S, et al. Effects of prostaglandins on Deoxyribonucleic acid and aggrecan synthesis in the RCJ 3.1C5.18 chondrocyte cell line: role of second messengers. Endocrinology. 1996;137:2208-2216
19. Moreno-Rubio J, Herrero-Beaumont G, Tardio L, Alvarez-Soria MA, Largo R. Nonsteroidal antiinflammatory drugs and prostaglandin E(2) modulate the synthesis of osteoprotegerin andRANKL in the cartilage of patients with severe knee osteoarthritis. Arthritis Rheum. 2010;62:478-488
20. Marcelon G, Cros J, Guiraud R. Activity of anti-inflammatory drugs on an experimental moDel of osteoarthritis. Agents Actions. 1976; 6:191-194
21. Fontagne J, Loizeau M, Adolphe M, Lechat P. Effect of indomethacin on collagen biosynthesis by rabbit articular chondrocytes in monolayer cultures. Int J Tissue React. 1984;6:233-241
22. Bassleer C, Magotteaux J, Geenen V, Malaise M. Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology. 1997;54:49-56
23. Dingle JT. The effects of NSAID on the matrix of human articular cartilages. Z Rheumatol. 1999;58:125-129
24. Chang JK, Wu SC, Wang GJ, Cho MH, Ho ML. Effects of nonsteroidal anti-inflammatory drugs on cell proliferation and Death in cultured epiphyseal-Articular chondrocytes of fetal rats. Toxicology. 2006;228:111-123
25. Iimoto S, Watanabe S, Takahashi T, Shimizu A, Yamamoto H. The influence of Celecoxib on matrix synthesis by chondrocytes unDer mechanical stress in vitro. Int J Mol Med. 2005;16:1083-1088
26. Jeffrey JE, AspDen RM. Cyclooxygenase inhibition lowers prostaglandin E2 release from articular cartilage and reduces apoptosis but not proteoglycan Degradation following an impact load in vitro. Arthritis Res Ther. 2007;9:R129
27. Alvarez-Soria MA, Herrero-Beaumont G, Moreno-Rubio J, Calvo E, Santillana J, Egido J, Largo R. Long-term NSAID treatment directly Decreases COX-2 and mPGES-1 production in the articular cartilage of patients with osteoarthritis. Osteoarthritis Cartilage. 2008;16:1484-1493
28. Brochhausen C, Neuland P, Kirkpatrick CJ, Nusing RM, Klaus G. Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ-prostaglandin E2 DepenDent proliferation of growth plate chondrocytes. Arthritis Res Ther. 2006; 8:R78
29. Hutchison MR, Bassett MH, White PC. SCF, BDNF, and Gas6 are regulators of growth plate chondrocyte proliferation and differentiation. Mol Endocrinol. 2010;24:193-203
30. Sylvia VL, Del Toro F Jr, Hardin RR, Dean DD, Boyan BD, Schwartz Z. Characterization of PGE(2) receptors (EP) and their role as mediators of 1,25-(OH)(2)D(3) effects on growth zone chondrocytes. J Steroid Biochem Mol Biol. 2001;78:261-274
31. Li TF, Zuscik MJ, Ionescu AM, et al. PGE2 inhibits chondrocyte differentiation throughPKAandPKCsignaling.ExpCell Res. 2004; 300:159-169
32. Welting TJ, Caron MM, Emans PJ, et al. Inhibition of cyclooxygenase-2 impacts chondrocyte hypertrophic differentiation during endochondral ossification. Eur Cell Mater. 2011;22:420-436; discussion 436-427
33. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97-120
34. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000;69:145-182
35. Blanco FJ, Guitian R, Moreno J, De Toro FJ, Galdo F. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. J Rheumatol. 1999;26:1366-1373
36. Adams SS, Bough RG, Cliffe EE, et al. Some aspects of the pharmacology, metabolism, and toxicology of ibuprofen. I. Pharmacology and metabolism. Rheumatol Phys Med. 1970;10(suppl 10):19-26
37. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum. 1996;26:435-446
38. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: iDentification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamiDe (SC-58635, celecoxib). J Med Chem. 1997;40:1347-1365
39. Van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential. Expert Opin Investig Drugs. 1997;6:609-614
40. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277
41. Beharry KD, Modanlou HD, Hasan J, et al. Comparative effects of early postnatal ibuprofen and indomethacin on VEGF, IGF-I, and GH during rat ocular Development. Invest Ophthalmol Vis Sci. 2006;47:3036-3043
42. Srgel F, Fuhr U, Minic M, et al. Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. Int J Clin Pharmacol Ther. 2005;43:140-149
43. Brown RD, Wilson JT, Kearns GL, Eichler VF, Johnson VA, Bertrand KM. Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children. J Clin Pharmacol. 1992;32:231-241
44. Paulson SK, Vaughn MB, Jessen SM, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297:638-645
45. Macrae VE,AhmedSF, Mushtaq T, Farquharson C. IGF-I signalling in bone growth: inhibitory actions of Dexamethasone and IL-1. Growth Horm IGF Res. 2007;17:435-439
46. Yonekura A, Osaki M, Hirota Y, et al. Transforming growth factor-stimulates articular chondrocyte cell growth through p44/42 MAP kinase (ERK) activation. Endocr J. 1999;46:545-553
47. Ciarmatori S, Kiepe D, Haarmann A, Huegel U, Tnshoff B. Signaling mechanisms leading to regulation of proliferation and differentiation of the mesenchymal chondrogenic cell line RCJ3.1C5.18 in response to IGF-I. J Mol Endocrinol. 2007;38:493-508
48. Fortier I, Patry C, Lora M, Samadfan R, De Brum-FernanDes AJ. Immunohistochemical localization of the prostacyclin receptor (IP) human bone. Prostaglandins Leukot Essent Fatty Acids. 2001;65: 79-83
49. Burgering BM, Pronk GJ, Van Weeren PC, Chardin P, Bos JL.cAMP antagonizes p21ras-directed activation of extracellular signal-regulated kinase 2 and phosphorylation of mSos nucleotiDe exchange factor. EMBO J. 1993;12:4211-4220
50. Cook SJ, McCormick F. Inhibition by cAMP of Ras-DepenDent activation of Raf. Science. 1993;262:1069-1072
51. Graves LM, Bornfeldt KE, Raines EW, et al. Protein kinase A antagonizes platelet-Derived growth factor-induced signaling by mitogen-Activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA. 1993;90:10300-10304
52. Frdin M, Peraldi P, Van Obberghen E. Cyclic AMP activates the mitogen-Activated protein kinase cascaDe inPC12cells. J BiolChem. 1994;269:6207-6214
53. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci. 2006;31:680-686
54. Vossler MR, Yao H, York RD, Pan MG, Rim CS, Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf-And Rap1-DepenDent pathway. Cell. 1997;89:73-82
55. Yao H, York RD, Misra-Press A, Carr DW, Stork PJ. The cyclic aDenosine monophosphate-DepenDent protein kinase (PKA) is required for the sustained activation of mitogen-Activated kinases and gene expression by nerve growth factor. J Biol Chem. 1998;273: 8240-8247
56. Espinosa M, Gottlieb BS. Juvenile idiopathic arthritis. Pediatr Rev. 2012;33:303-313
57. Ji P, Chowdhury BA, Yim S, Sahajwalla CG. Dosing regimen Determination for juvenile idiopathic arthritis: a review of studies during drug Development. J Pharm Sci. 2012;101:2621-2634
58. Kiely PD, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford). 2009;48:765-772
59. ADebajo.Anon-steroidal anti-inflammatory drugs for the treatment of pain and immobility-Associated osteoarthritis: consensus guidance for primary care. BMC Fam Pract. 2012;13:23
60. Zhang L, Jiang L, Sun Q, et al. Prostaglandin E2 enhances mitogenactivated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium anDeGFreceptors signaling. Mol Cell Biochem. 2007;305:19-26
61. Krysan K, Reckamp KL, Dalwadi H, et al. Prostaglandin E2 activates mitogen-Activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epiDermal growth factor receptor-inDepenDent manner. Cancer Res. 2005;65: 6275-6281
62. Pozzi A, Yan X, Macias-Perez I, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem. 2004;279:29797-29804
63. Sasaki E, Tominaga K, Watanabe T, et al. COX-2 is essential for EGF induction of cell proliferation in gastric RGM1 cells. Dig Dis Sci. 2003;48:2257-2262
64. Chagin AS, Vuppalapati KK, Kobayashi T, et al. G-protein stimulatory subunit and Gq/11 G-proteins are both required to maintain quiescent stem-like chondrocytes. Nat Commun. 2014;5:3673
65. Linglart A, Fryssira H, Hiort O, et al. PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance. J Clin Endocrinol Metab. 2012;97:E2328-E2338
66. Abramovitz M, Adam M, Boie Y, et al. The utilization of recombinant prostanoid receptors to Determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000; 1483:285-293
67. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122:217-224
68. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferator-Activated receptor (PPAR) ligand 15-Deoxy-12, 14-prostaglandin J2. J Biol Chem. 1999;274:17042-17048
69. Reginato MJ, Krakow SL, Bailey ST, Lazar MA. Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-Activated receptor . J Biol Chem. 1998;273: 1855-1858
70. Lim H, Dey SK. A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology. 2002;143:3207-3210
71. Schwartz Z, Gilley RM, Sylvia VL, Dean DD, Boyan BD. The effect of prostaglandin E2 on costochondral chondrocyte differentiation is mediated by cyclic aDenosine 3,5-monophosphate and protein kinase C. Endocrinology. 1998;139:1825-1834
72. Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell. 1995;83:483-492
73. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83:473-482
74. Dinchuk JE, Car BD, Focht RJ, et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409
75. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388:678-682
76. Gerits N, Kostenko S, Shiryaev A, Johannessen M, Moens U. Relations between the mitogen-Activated protein kinase and thecAMPDepenDent protein kinase pathways: comraDeship and hostility. Cell Signal. 2008;20:1592-1607.